Celldex Therapeutics, Inc. cash flow to debt ratio of -9.03K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Celldex Therapeutics, Inc.'s free cash flow has decreased 33.79% from $-159.70M last year to $-213.66M, signaling decreasing performance

Celldex Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Celldex Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

Celldex Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Celldex Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Celldex Therapeutics, Inc.'s profit margin has decreased (1.44K%) in the last year from -2.25K% to -34.60K%, signaling decreasing performance

Celldex Therapeutics, Inc.'s short-term assets of $534.66M exceed its short-term liabilities of $50.99M

Celldex Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Celldex Therapeutics, Inc.'s return on equity of -50.72%, is lower than 15.00%, indicating bad performance

Celldex Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Celldex Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Celldex Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Celldex Therapeutics, Inc. has negative free cash flow, indicating cash burn

Celldex Therapeutics, Inc.'s yearly earnings has decreased 63.94% since last year from $-157.86M to $-258.80M, signaling decreasing performance

Celldex Therapeutics, Inc.'s yearly revenue has decreased -78.63% since last year from $7.02M to $1.50M, signaling decreasing performance

ROIC -67.01% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Celldex Therapeutics, Inc.'s 3-year revenue CAGR of -13.98% is negative, indicating declining revenue over the past 3 years

Celldex Therapeutics, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Celldex Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Celldex Therapeutics, Inc. has insufficient data to evaluate this check.

Celldex Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Celldex Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Celldex Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Celldex Therapeutics, Inc. is overvalued relative to its fair value price of -4.21 based on Earnings Fair Value model

Celldex Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Celldex Therapeutics, Inc. has a price-to-book ratio of 5.57x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Celldex Therapeutics, Inc. has a price-to-sales ratio of 3.10Kx, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue